New rabies vaccine from Sanofi approved in the EU
Published
The pharmaceutical company Sanofi has received approval in the EU for a new vaccine against rabies. The approval applies across the whole union, so it also covers Sweden.
The new vaccine has a longer shelf life than earlier vaccines. It also tolerates temperature changes better. This means the vaccine can be stored for longer and is less sensitive during transport and handling.
Rabies is a viral disease that is most often spread through bites from animals. If treatment is not given in time, the disease can be fatal. In Sweden, rabies is very rare, but people who travel to countries where the disease is more common may need to be vaccinated. The vaccine can also be used to protect people who have been at risk of infection.
The article does not say when the new vaccine will become available in Sweden or what price it will have. It is therefore unclear when Swedish health centres and pharmacies can start using it.
Sources: www.lifesciencefocus.com
More Sweden news
- Slow start for Sverige-id: authorities can get up to nine months' exemption
- Marcus Bergman leaves Sweden after more than 400 matches in Hockeyallsvenskan
- Trust in Sweden could affect the country's defence capability
- Danish drugmaker LEO Pharma postpones its stock market listing
- This is what the Swedish royals are really like, according to an expert
- Musikhjälpen 2026: The first prize is tickets to a Premier League match
- Business leaders impatient with AI: small progress is no longer enough
- Sweden expected to attract twice as much venture capital this year